CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: SOLID TUMOR TESTING MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Genetic Testing
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Genetic Testing Solid Tumor Testing Market by Genetic Test Type
4.2.4.1 Next generation sequencing (NGS) Market size and forecast, by region
4.2.4.2 Real-time PCR (RT-PCR) Market size and forecast, by region
4.2.4.3 Fluorescent In-Situ Hybridization (FISH) Market size and forecast, by region
4.2.4.4 Fragment Analysis Market size and forecast, by region
4.3 Conventional Testing
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: SOLID TUMOR TESTING MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Prostate
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Breast
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Colorectal
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Endometrial
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Lung
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Melanoma
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Brain
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
5.9 Thyroid
5.9.1 Key market trends, growth factors and opportunities
5.9.2 Market size and forecast, by region
5.9.3 Market analysis by country
6.0 Liver
6.0.1 Key market trends, growth factors and opportunities
6.0.2 Market size and forecast, by region
6.0.3 Market analysis by country
6.1 Ovarian
6.1.1 Key market trends, growth factors and opportunities
6.1.2 Market size and forecast, by region
6.1.3 Market analysis by country
6.2 Others
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
CHAPTER 6: SOLID TUMOR TESTING MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Pharmaceutical and biotechnology companies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Contract research organizations
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Academic research institutions
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: SOLID TUMOR TESTING MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.2.1 North America Genetic Testing Solid Tumor Testing Market by Genetic Test Type
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.2.1 Europe Genetic Testing Solid Tumor Testing Market by Genetic Test Type
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.2.1 Asia-Pacific Genetic Testing Solid Tumor Testing Market by Genetic Test Type
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.2.1 LAMEA Genetic Testing Solid Tumor Testing Market by Genetic Test Type
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 QIAGEN
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 QUEST DIAGNOSTICS INCORPORATED
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Abbott Laboratories
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Agilent Technologies Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Biocare Medical LLC
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 , F. Hoffmann-La Roche AG
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 ILLUMINA, INC.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 MedGenome Labs Private Ltd
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 MYRIAD GENETICS, INC.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Thermo Fisher Scientific, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. SOLID TUMOR TESTING MARKET, FOR GENETIC TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 3. SOLID TUMOR TESTING MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
TABLE 5. SOLID TUMOR TESTING MARKET, FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2021-2031 ($MILLION)
TABLE 6. SOLID TUMOR TESTING MARKET, FOR REAL-TIME PCR (RT-PCR), BY REGION, 2021-2031 ($MILLION)
TABLE 7. SOLID TUMOR TESTING MARKET, FOR FLUORESCENT IN-SITU HYBRIDIZATION (FISH), BY REGION, 2021-2031 ($MILLION)
TABLE 8. SOLID TUMOR TESTING MARKET, FOR FRAGMENT ANALYSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. SOLID TUMOR TESTING MARKET, FOR CONVENTIONAL TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 10. SOLID TUMOR TESTING MARKET FOR CONVENTIONAL TESTING, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. GLOBAL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 12. SOLID TUMOR TESTING MARKET, FOR PROSTATE, BY REGION, 2021-2031 ($MILLION)
TABLE 13. SOLID TUMOR TESTING MARKET FOR PROSTATE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. SOLID TUMOR TESTING MARKET, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
TABLE 15. SOLID TUMOR TESTING MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. SOLID TUMOR TESTING MARKET, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
TABLE 17. SOLID TUMOR TESTING MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. SOLID TUMOR TESTING MARKET, FOR ENDOMETRIAL, BY REGION, 2021-2031 ($MILLION)
TABLE 19. SOLID TUMOR TESTING MARKET FOR ENDOMETRIAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. SOLID TUMOR TESTING MARKET, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
TABLE 21. SOLID TUMOR TESTING MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. SOLID TUMOR TESTING MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 23. SOLID TUMOR TESTING MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. SOLID TUMOR TESTING MARKET, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
TABLE 25. SOLID TUMOR TESTING MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. SOLID TUMOR TESTING MARKET, FOR THYROID, BY REGION, 2021-2031 ($MILLION)
TABLE 27. SOLID TUMOR TESTING MARKET FOR THYROID, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. SOLID TUMOR TESTING MARKET, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
TABLE 29. SOLID TUMOR TESTING MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. SOLID TUMOR TESTING MARKET, FOR OVARIAN, BY REGION, 2021-2031 ($MILLION)
TABLE 31. SOLID TUMOR TESTING MARKET FOR OVARIAN, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. SOLID TUMOR TESTING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 33. SOLID TUMOR TESTING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. GLOBAL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 35. SOLID TUMOR TESTING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 36. SOLID TUMOR TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. SOLID TUMOR TESTING MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
TABLE 38. SOLID TUMOR TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 39. SOLID TUMOR TESTING MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 40. SOLID TUMOR TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 41. SOLID TUMOR TESTING MARKET, FOR ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 42. SOLID TUMOR TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. SOLID TUMOR TESTING MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 44. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. NORTH AMERICA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
TABLE 46. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 47. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 48. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. U.S. SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 50. U.S. SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 51. U.S. SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. CANADA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 53. CANADA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 54. CANADA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 55. MEXICO SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 56. MEXICO SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 57. MEXICO SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 58. EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 59. EUROPE GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
TABLE 60. EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 61. EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. EUROPE SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 63. GERMANY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 64. GERMANY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. GERMANY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 66. FRANCE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. FRANCE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 68. FRANCE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 69. UK SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 70. UK SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. UK SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. ITALY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 73. ITALY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74. ITALY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 75. SPAIN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 76. SPAIN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 77. SPAIN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 78. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. ASIA-PACIFIC GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
TABLE 83. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 86. JAPAN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. JAPAN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 88. JAPAN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 89. CHINA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. CHINA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 91. CHINA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 92. AUSTRALIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93. AUSTRALIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 94. AUSTRALIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 95. INDIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 96. INDIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 97. INDIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 98. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 99. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 100. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 101. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 102. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 103. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 104. LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 105. LAMEA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)
TABLE 106. LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 107. LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 108. LAMEA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 109. BRAZIL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 110. BRAZIL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 111. BRAZIL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 112. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 113. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 114. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 115. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 116. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 117. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 118. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 119. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 120. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 121.QIAGEN: COMPANY SNAPSHOT
TABLE 122.QIAGEN: OPERATING SEGMENTS
TABLE 123.QIAGEN: PRODUCT PORTFOLIO
TABLE 124.QIAGEN: NET SALES,
TABLE 125.QIAGEN: KEY STRATERGIES
TABLE 126.QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
TABLE 127.QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS
TABLE 128.QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
TABLE 129.QUEST DIAGNOSTICS INCORPORATED: NET SALES,
TABLE 130.QUEST DIAGNOSTICS INCORPORATED: KEY STRATERGIES
TABLE 131.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 132.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 133.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 134.ABBOTT LABORATORIES: NET SALES,
TABLE 135.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 136.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 137.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
TABLE 138.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
TABLE 139.AGILENT TECHNOLOGIES INC.: NET SALES,
TABLE 140.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES
TABLE 141.BIOCARE MEDICAL LLC: COMPANY SNAPSHOT
TABLE 142.BIOCARE MEDICAL LLC: OPERATING SEGMENTS
TABLE 143.BIOCARE MEDICAL LLC: PRODUCT PORTFOLIO
TABLE 144.BIOCARE MEDICAL LLC: NET SALES,
TABLE 145.BIOCARE MEDICAL LLC: KEY STRATERGIES
TABLE 146., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 147., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 148., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 149., F. HOFFMANN-LA ROCHE AG: NET SALES,
TABLE 150., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 151.ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 152.ILLUMINA, INC.: OPERATING SEGMENTS
TABLE 153.ILLUMINA, INC.: PRODUCT PORTFOLIO
TABLE 154.ILLUMINA, INC.: NET SALES,
TABLE 155.ILLUMINA, INC.: KEY STRATERGIES
TABLE 156.MEDGENOME LABS PRIVATE LTD: COMPANY SNAPSHOT
TABLE 157.MEDGENOME LABS PRIVATE LTD: OPERATING SEGMENTS
TABLE 158.MEDGENOME LABS PRIVATE LTD: PRODUCT PORTFOLIO
TABLE 159.MEDGENOME LABS PRIVATE LTD: NET SALES,
TABLE 160.MEDGENOME LABS PRIVATE LTD: KEY STRATERGIES
TABLE 161.MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
TABLE 162.MYRIAD GENETICS, INC.: OPERATING SEGMENTS
TABLE 163.MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
TABLE 164.MYRIAD GENETICS, INC.: NET SALES,
TABLE 165.MYRIAD GENETICS, INC.: KEY STRATERGIES
TABLE 166.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 167.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 168.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 169.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 170.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
